These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28107598)

  • 1. Dropout in clinical trials of pharmacological treatment for methamphetamine dependence: the role of initial abstinence.
    Cook R; Quinn B; Heinzerling K; Shoptaw S
    Addiction; 2017 Jun; 112(6):1077-1085. PubMed ID: 28107598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Placebo-group responders in methamphetamine pharmacotherapy trials: the role of immediate establishment of abstinence.
    Brensilver M; Heinzerling KG; Swanson AN; Shoptaw SJ
    Exp Clin Psychopharmacol; 2012 Oct; 20(5):430-5. PubMed ID: 22867036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapy for methamphetamine/amphetamine use disorder-a systematic review and meta-analysis.
    Chan B; Freeman M; Kondo K; Ayers C; Montgomery J; Paynter R; Kansagara D
    Addiction; 2019 Dec; 114(12):2122-2136. PubMed ID: 31328345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial.
    Anderson AL; Li SH; Markova D; Holmes TH; Chiang N; Kahn R; Campbell J; Dickerson DL; Galloway GP; Haning W; Roache JD; Stock C; Elkashef AM
    Drug Alcohol Depend; 2015 May; 150():170-4. PubMed ID: 25818061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of reduced use and abstinence in multi-site randomized controlled trials of pharmacotherapies for cocaine and methamphetamine use disorders.
    Amin-Esmaeili M; Susukida R; Johnson RM; Farokhnia M; Crum RM; Thrul J; Mojtabai R
    Drug Alcohol Depend; 2021 Sep; 226():108904. PubMed ID: 34304121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder.
    Ling W; Chang L; Hillhouse M; Ang A; Striebel J; Jenkins J; Hernandez J; Olaer M; Mooney L; Reed S; Fukaya E; Kogachi S; Alicata D; Holmes N; Esagoff A
    Addiction; 2014 Sep; 109(9):1489-500. PubMed ID: 24825486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of Relapse and Dropout During a 12-Week Relapse Prevention Program for Methamphetamine Users.
    Chen YC; Chen CK; Wang LJ
    J Psychoactive Drugs; 2015; 47(4):317-24. PubMed ID: 26267045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: Findings from 13 multisite randomized clinical trials.
    Amin-Esmaeili M; Farokhnia M; Susukida R; Leggio L; Johnson RM; Crum RM; Mojtabai R
    Addiction; 2024 May; 119(5):833-843. PubMed ID: 38197836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychosocial interventions for cannabis use disorder.
    Gates PJ; Sabioni P; Copeland J; Le Foll B; Gowing L
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD005336. PubMed ID: 27149547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, Placebo-Controlled Trial of Targeting Neuroinflammation with Ibudilast to Treat Methamphetamine Use Disorder.
    Heinzerling KG; Briones M; Thames AD; Hinkin CH; Zhu T; Wu YN; Shoptaw SJ
    J Neuroimmune Pharmacol; 2020 Jun; 15(2):238-248. PubMed ID: 31820289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective analysis of two randomized trials of bupropion for methamphetamine dependence: suggested guidelines for treatment discontinuation/augmentation.
    Brensilver M; Heinzerling KG; Swanson AN; Shoptaw SJ
    Drug Alcohol Depend; 2012 Sep; 125(1-2):169-72. PubMed ID: 22534658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dropout rates of in-person psychosocial substance use disorder treatments: a systematic review and meta-analysis.
    Lappan SN; Brown AW; Hendricks PS
    Addiction; 2020 Feb; 115(2):201-217. PubMed ID: 31454123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of psychostimulants for amphetamine and methamphetamine use disorders: a systematic review and meta-analysis.
    Bhatt M; Zielinski L; Baker-Beal L; Bhatnagar N; Mouravska N; Laplante P; Worster A; Thabane L; Samaan Z
    Syst Rev; 2016 Nov; 5(1):189. PubMed ID: 27842569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials.
    Kishi T; Matsuda Y; Iwata N; Correll CU
    J Clin Psychiatry; 2013 Dec; 74(12):e1169-80. PubMed ID: 24434105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence.
    Ezard N; Dunlop A; Hall M; Ali R; McKetin R; Bruno R; Phung N; Carr A; White J; Clifford B; Liu Z; Shanahan M; Dolan K; Baker AL; Lintzeris N
    BMJ Open; 2018 Jul; 8(7):e020723. PubMed ID: 30030312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, placebo-controlled trial of aripiprazole for the treatment of methamphetamine dependence and associated psychosis.
    Sulaiman AH; Gill JS; Said MA; Zainal NZ; Hussein HM; Guan NC
    Int J Psychiatry Clin Pract; 2013 Jun; 17(2):131-8. PubMed ID: 22486597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spending money to make change: Association of methamphetamine abstinence and voucher spending among contingency management pilot participants in South Africa.
    Krishnamurti T; Ling Murtaugh K; Van Nunen L; Davis AL; Ipser J; Shoptaw S
    J Subst Abuse Treat; 2020 May; 112():60-67. PubMed ID: 32199547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended-release naltrexone for methamphetamine dependence among men who have sex with men: a randomized placebo-controlled trial.
    Coffin PO; Santos GM; Hern J; Vittinghoff E; Santos D; Matheson T; Colfax G; Batki SL
    Addiction; 2018 Feb; 113(2):268-278. PubMed ID: 28734107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of prospectively determined A118G polymorphism on treatment response to injectable naltrexone among methamphetamine-dependent patients: an open-label, pilot study.
    Pal R; Mendelson JE; Flower K; Garrison K; Yount G; Coyle JR; Galloway GP
    J Addict Med; 2015; 9(2):130-5. PubMed ID: 25622123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bupropion for the treatment of methamphetamine dependence.
    Elkashef AM; Rawson RA; Anderson AL; Li SH; Holmes T; Smith EV; Chiang N; Kahn R; Vocci F; Ling W; Pearce VJ; McCann M; Campbell J; Gorodetzky C; Haning W; Carlton B; Mawhinney J; Weis D
    Neuropsychopharmacology; 2008 Apr; 33(5):1162-70. PubMed ID: 17581531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.